JAZZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Jazz Pharmaceuticals (JAZZ) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive growth potential and favorable analyst ratings, insider selling and lack of strong immediate trading signals suggest waiting for a clearer entry point.
The stock shows a bullish trend with moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram (0.758). However, RSI is neutral (61.816), and there is no clear momentum signal. Key resistance levels are at 200.83 and 205.171, while support levels are at 193.803 and 186.776.
Analysts maintain strong ratings with price targets ranging from $220 to $275, indicating potential upside.
The company's Q4 2025 financials show revenue growth (+10.09% YoY), net income growth (+6.45% YoY), and EPS growth (+7.07% YoY).
The oncology and central nervous system franchises provide long-term growth visibility.
Insider selling has increased significantly (+385.47% over the last month), which could signal reduced confidence from insiders.
Lack of recent news or event-driven catalysts.
Gross margin dropped slightly (-0.76% YoY), which may indicate cost pressures.
In Q4 2025, Jazz Pharmaceuticals reported revenue growth of 10.09% YoY to $1.197 billion, net income growth of 6.45% YoY to $203.45 million, and EPS growth of 7.07% YoY to $3.33. However, gross margin declined slightly to 73.01% (-0.76% YoY).
Analysts are overwhelmingly positive on JAZZ, with multiple firms raising price targets recently. The average price target is above $220, with the highest at $275. Analysts highlight strong growth visibility and undervaluation, but note competitive risks in the oxybate franchise.
